GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InfuSystems Holdings Inc (AMEX:INFU) » Definitions » Cash Conversion Cycle

INFU (InfuSystems Holdings) Cash Conversion Cycle : 42.06 (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is InfuSystems Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

InfuSystems Holdings's Days Sales Outstanding for the three months ended in Sep. 2024 was 56.95.
InfuSystems Holdings's Days Inventory for the three months ended in Sep. 2024 was 37.95.
InfuSystems Holdings's Days Payable for the three months ended in Sep. 2024 was 52.84.
Therefore, InfuSystems Holdings's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2024 was 42.06.


InfuSystems Holdings Cash Conversion Cycle Historical Data

The historical data trend for InfuSystems Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InfuSystems Holdings Cash Conversion Cycle Chart

InfuSystems Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.98 8.48 21.65 26.06 38.32

InfuSystems Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.12 46.89 42.42 38.88 42.06

Competitive Comparison of InfuSystems Holdings's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, InfuSystems Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InfuSystems Holdings's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where InfuSystems Holdings's Cash Conversion Cycle falls into.



InfuSystems Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

InfuSystems Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=53.25+32.68-47.61
=38.32

InfuSystems Holdings's Cash Conversion Cycle for the quarter that ended in Sep. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=56.95+37.95-52.84
=42.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InfuSystems Holdings  (AMEX:INFU) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


InfuSystems Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of InfuSystems Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


InfuSystems Holdings Business Description

Traded in Other Exchanges
Address
3851 West Hamlin Road, Rochester Hills, MI, USA, 48309
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
Executives
Richard Dilorio officer: Executive Vice President 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Boyd Ralph F Jr director
Addam Chupa officer: Executive VP and CIO 3851 WEST HAMLIN ROAD, ROCHESTER HILLS MI 48309
Jerod Funke officer: EVP-Chief HR Officer 3851 WEST HAMLIN RD, ROCHESTER HILLS MI 48309
Paul Andrew Gendron director 740 BANDIT TRAIL, KELLER TX 76248
Barry G Steele officer: Executive VP and CFO 500 TOWN CENTER DR., SUITE 200, DEARBORN MI 48126
R. Rimmy Malhotra director C/O COMMAND CENTER, INC., 3609 S WADSWORTH BLVD., SUITE 250, LAKEWOOD CO 80235
Gregg Owen Lehman director 309 HADDON COURT, FRANKLIN X1 37067
Carrie Lachance officer: Executive VP and COO 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Christopher R. Sansone director C/O SANSONE ADVISORS, LLC, 151 BODMAN PLACE, SUITE 100, RED BANK NJ 07701
Kevin Whitman officer: VP and Corporate Controller 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Thomas Mark Ruiz officer: VP of Sales and Marketing 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Jeannine Sheehan officer: Chief Administrative Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Blueline Capital Partners Ii, L.p. director 3480 BUSKIRK AVENUE, SUITE 214, PLEASANT HILL CA 94523
Meridian Tsv Ii, Lp 10 percent owner 405 WEED STREET, NEW CANAAN CT 06840